Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Kreis, Kristine; Horenkamp-Sonntag, Dirk; Schneider, Udo; Zeidler, Jan; Glaeske, Gerd; Weissbach, Lothar: Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study. In: PharmacoEconomics Open (2020), in press. DOI: https://doi.org/10.1007/s41669-020-00219-6
- Event
-
Veröffentlichung
- (where)
-
Hannover
- (who)
-
Gottfried Wilhelm Leibniz Universität Hannover
- (when)
-
2020
- Event
-
Veröffentlichung
- (where)
-
Hannover
- (who)
-
Technische Informationsbibliothek (TIB)
- (when)
-
2020
- Creator
- DOI
-
10.15488/9955
- URN
-
urn:nbn:de:101:1-2020080811072719338278
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:44 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kreis, Kristine
- Horenkamp-Sonntag, Dirk
- Schneider, Udo
- Zeidler, Jan
- Glaeske, Gerd
- Weissbach, Lothar
- Gottfried Wilhelm Leibniz Universität Hannover
- Technische Informationsbibliothek (TIB)
Time of origin
- 2020
Other Objects (12)
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy
Identification of genomic alterations in castration resistant prostate cancer using next generation sequencing
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy
Identification of genomic alterations in castration resistant prostate cancer using next generation sequencing
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy